A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T.
Wacheck V, et al. Among authors: fuereder t.
J Infect Dis. 2010 Feb 1;201(3):354-62. doi: 10.1086/649428.
J Infect Dis. 2010.
PMID: 20039806
Clinical Trial.